Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 18.104.22.168) - Pipeline Review, H1 2018
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 22.214.171.124) pipeline Target constitutes close to 36 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 126.96.36.199) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 188.8.131.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin.
This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immuno regulation, and antioxidant activity. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 7, 3, 11 and 4 respectively.
Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Metastatic Melanoma, Glioblastoma Multiforme (GBM), Bladder Cancer, Adenocarcinoma, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Alopecia, B-Cell Non-Hodgkin Lymphoma, Brain Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Ependymoma, Gastric Cancer, Glioma, Gliosarcoma, Head And Neck Cancer, Hematological Tumor, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Lung Cancer, Malignant Glioma, Medulloblastoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Ocular Melanoma, Ovarian Cancer, Psoriasis, Renal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Type 1 Diabetes (Juvenile Diabetes).
Furthermore, this report also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 184.108.40.206) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook